Applied Genetic Technologies : ACHM 12-Month Data Presentation

June 24, 2021

This presentation contains forward-looking statements that reflect Applied Genetic Technologies Corporation's ("AGTC" or the "Company") plans, estimates, assumptions and beliefs. Forward-looking statements include statements regarding AGTC's proposed clinical development of ACHMB3, planned pediatric surgeries for its ACHM clinical programs and the potential results thereof, its ability to enroll patients for its clinical trials, regulatory progress, potential growth and market opportunities, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Actual results could differ materially from those discussed in the forward-looking statements, due to a number of important factors. Risks and uncertainties that may cause actual results to differ materially include, among others: that AGTC cannot predict when or if it will obtain regulatory approval to continue to progress its clinical trials, commercialize a product candidate or receive reasonable reimbursement; uncertainty inherent in clinical trials and the regulatory review process; risks and uncertainties associated with drug development and commercialization; risks related to the COVID-19 outbreak that may delay clinical trial enrollment; and that gene therapy is still novel with only a few approved treatments so far. Factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent periodic reports filed with the SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management's plans, estimates, assumptions and beliefs only as of the date of this presentation. Except as required by law, AGTC assumes no obligation to update or revise these forward-looking statements publicly, whether as a result of new information, new events or

otherwise.

• Introduction
• ACHM Data Review
• Q&A

37 Adult Patients, 8 patients under 18

OVERVIEW

• Approximately 27,000 patients in US and EU affected
• AGTC focused on A3 and B3 gene mutations
• • B3 accounts for approximately 50% or 14,000 patients
  • A3 accounts for approximately 25% or 7,000 patients
• Severely impaired vision and day blindness due to loss of cone photoreceptor function
• No current treatments

IMPACT

• Extremely poor vision, legally blind
• Extreme light sensitivity (day blind)
• Complete loss of color discrimination